The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

Yousef Zakharia, MD
Published Online:3:06 PM, Thu April 6, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.